445 related articles for article (PubMed ID: 25074246)
1. Patterns of use and tolerance of anti-epidermal growth factor receptor antibodies in older adults with metastatic colorectal cancer.
Dotan E; Devarajan K; D'Silva AJ; Beck A; Kloth DD; Cohen SJ; Denlinger C
Clin Colorectal Cancer; 2014 Sep; 13(3):192-8. PubMed ID: 25074246
[TBL] [Abstract][Full Text] [Related]
2. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
3. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
Kishiki T; Ohnishi H; Masaki T; Ohtsuka K; Ohkura Y; Furuse J; Watanabe T; Sugiyama M
Cancer Chemother Pharmacol; 2014 Apr; 73(4):749-57. PubMed ID: 24500024
[TBL] [Abstract][Full Text] [Related]
5. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
Douillard JY; Siena S; Cassidy J; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Oliner KS; Wolf M; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4697-705. PubMed ID: 20921465
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
7. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
8. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients.
Martin V; Landi L; Molinari F; Fountzilas G; Geva R; Riva A; Saletti P; De Dosso S; Spitale A; Tejpar S; Kalogeras KT; Mazzucchelli L; Frattini M; Cappuzzo F
Br J Cancer; 2013 Feb; 108(3):668-75. PubMed ID: 23348520
[TBL] [Abstract][Full Text] [Related]
9. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy.
Allegra CJ; Jessup JM; Somerfield MR; Hamilton SR; Hammond EH; Hayes DF; McAllister PK; Morton RF; Schilsky RL
J Clin Oncol; 2009 Apr; 27(12):2091-6. PubMed ID: 19188670
[TBL] [Abstract][Full Text] [Related]
11. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
Oncologist; 2012; 17(1):14. PubMed ID: 22210091
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
13. Review article: panitumumab--a fully human anti-EGFR monoclonal antibody for treatment of metastatic colorectal cancer.
Peeters M; Balfour J; Arnold D
Aliment Pharmacol Ther; 2008 Aug; 28(3):269-81. PubMed ID: 19086328
[TBL] [Abstract][Full Text] [Related]
14. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer.
Abrams TA; Meyer G; Schrag D; Meyerhardt JA; Moloney J; Fuchs CS
J Natl Cancer Inst; 2014 Feb; 106(2):djt371. PubMed ID: 24511107
[TBL] [Abstract][Full Text] [Related]
16. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
17. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.
Tol J; Koopman M; Cats A; Rodenburg CJ; Creemers GJ; Schrama JG; Erdkamp FL; Vos AH; van Groeningen CJ; Sinnige HA; Richel DJ; Voest EE; Dijkstra JR; Vink-Börger ME; Antonini NF; Mol L; van Krieken JH; Dalesio O; Punt CJ
N Engl J Med; 2009 Feb; 360(6):563-72. PubMed ID: 19196673
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer.
Takahashi N; Yamada Y; Furuta K; Honma Y; Iwasa S; Takashima A; Kato K; Hamaguchi T; Shimada Y
Br J Cancer; 2014 May; 110(11):2716-27. PubMed ID: 24800946
[TBL] [Abstract][Full Text] [Related]
19. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
